- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07426250
과소전이성 질환 치료에서 순환종양DNA(ctDNA)의 임상적 유용성
올리고전이성 질환 치료에서 ctDNA의 임상적 유용성 - 전향적 관찰 임상 연구 - POB-프로젝트의 일부
This prospective observational study investigates the clinical utility of circulating tumor DNA (ctDNA) in patients with oligometastatic disease (OMD) undergoing definitive-intent local ablative treatment (LAT). The study aims to evaluate ctDNA as a prognostic and response biomarker before, during, and after LAT across cancer types and treatment modalities. Serial plasma samples and archival tumor tissue will be analyzed to assess ctDNA detection rates, elimination patterns, minimal residual disease, and association with recurrence, progression, and survival outcomes.
연구 개요
상태
정황
상세 설명
Oligometastatic disease (OMD) represents an intermediate disease state between localized and polymetastatic cancer and may be amenable to curative or long-term disease-controlling local ablative treatment (LAT). Despite careful patient selection, recurrence rates after LAT remain substantial, highlighting the need for improved biological markers to guide treatment decisions and follow-up.
Circulating tumor DNA (ctDNA) is a promising biomarker for prognostication, response assessment, and early detection of recurrence. Pilot studies and systematic reviews conducted by the study group indicate that ctDNA dynamics before and after LAT are associated with treatment outcomes. However, important knowledge gaps remain regarding ctDNA detection rates, elimination patterns, optimal sampling time points, and clinical relevance across metastatic sites, treatment modalities, and oligometastatic states.
This prospective observational study, conducted as part of the Pan-Cancer Oligometastatic Biology (POB) project, will enroll patients with oligometastatic solid tumors planned for definitive-intent LAT. Serial blood samples will be collected before treatment, during treatment when applicable, and throughout follow-up. ctDNA and total circulating free DNA will be analyzed using sensitive molecular techniques. Archival tumor tissue will be retrieved for tumor-informed analyses.
The study will evaluate ctDNA detection rates, elimination patterns, minimal residual disease, lead time to radiological recurrence, and associations with disease-free survival, progression-free survival, and overall survival. Exploratory analyses of immune-related biomarkers will also be performed. The results are expected to support improved biological stratification and monitoring strategies in oligometastatic disease.
연구 유형
등록 (추정된)
연락처 및 위치
연구 연락처
- 이름: Louise B Callesen, MD, PhD
- 전화번호: 30482884
- 이메일: Louicall@rm.dk
연구 연락처 백업
- 이름: Karen-Lise G Spindler, Professor, MD, PhD
- 전화번호: 91167244
- 이메일: K.g.spindler@oncology.au.dk
연구 장소
-
-
-
Aarhus N, 덴마크, 8200
- 모병
- Department of Oncology, Aarhus University Hospital
-
연락하다:
- Louise B Callesen, MD, PhD
- 전화번호: 30482884
- 이메일: Louicall@rm.dk
-
수석 연구원:
- Louise B Callesen, MD, PhD
-
수석 연구원:
- Karen-Lise G Spindler, Professor, MD, PhD
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
The study population consists of patients with verified oligometastatic cancer disease who are planned for local ablative therapy.
설명
Inclusion Criteria:
- Metastatic spread from histopathological diagnosed solid cancer
- Planned for LAT (local ablative therapy) for OMD (oligometastatic disease)
- ≥ 18 years
- Written and oral consent
Exclusion Criteria:
- Other cancer disease within 5 years
- Conditions that will contraindicate blood samples
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: COHORT
- 시간 관점: PROSPECTIVE
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Association between longitudinal ctDNA status and clinical outcomes after local ablative treatment
기간: During follow-up up to 5 years
|
Presence and dynamics of circulating tumor DNA (ctDNA) assessed before LAT, after LAT, and during follow-up, and their association with clinically relevant outcomes including radiologically confirmed recurrence or progression, survival status, and lead time to recurrence. |
During follow-up up to 5 years
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Detection rate of ctDNA prior to local ablative treatment
기간: Baseline (pre-LAT)
|
The proportion of patients with detectable circulating tumor DNA in plasma prior to initiation of local ablative treatment will be assessed. Detection rates will be evaluated overall and stratified by treatment modality, cancer type and metastatic site |
Baseline (pre-LAT)
|
|
Elimination patterns of ctDNA following local ablative treatment
기간: During follow-up up to 5 years
|
Changes in ctDNA levels following local ablative treatment will be analyzed to characterize elimination patterns over time. Changes in ctDNA will be assessed in relation to treatment modality, cancer type, metastatic site, and timing of sampling to evaluate biological response to treatment |
During follow-up up to 5 years
|
|
Correlation between ctDNA and pathological response
기간: During follow-up up to 5 years
|
ctDNA status and ctDNA changes will be correlated with pathological response |
During follow-up up to 5 years
|
|
Correlation between ctDNA and risk of recurrence or early progression
기간: Up to 5 years
|
The association between ctDNA and the subsequent risk of recurrence or early disease progression will be evaluated |
Up to 5 years
|
|
Correlation between ctDNA and disease-free survival or progression-free survival
기간: Up to 5 years
|
Disease-free survival or progression-free survival will be analyzed according to ctDNA status at baseline, post-treatment, and during follow-up to assess the prognostic value of ctDNA in patients treated with definitive-intent local ablative treatment |
Up to 5 years
|
|
Correlation between ctDNA and overall survival
기간: Up to 5 years
|
Overall survival will be analyzed according to ctDNA status at baseline, post-treatment, and during follow-up to assess the prognostic value of ctDNA in patients treated with definitive-intent local ablative treatment |
Up to 5 years
|
|
Rate of ctDNA-detected minimal residual disease
기간: up to 5 years
|
The proportion of patients with detectable ctDNA following completion of definitive-intent local ablative treatment, consistent with molecular minimal residual disease, will be determined and analyzed in relation to clinical outcomes |
up to 5 years
|
|
Lead time between ctDNA detection and imaging-confirmed recurrence or progression
기간: During follow-up up to 5 years
|
The time interval between first detection of ctDNA during follow-up and subsequent radiological confirmation of recurrence or progression will be calculated to estimate the potential lead time provided by ctDNA monitoring |
During follow-up up to 5 years
|
|
Exploratory analysis of total circulating free DNA
기간: Up to 5 years
|
Total circulating free DNA levels will be quantified and analyzed exploratorily in relation to treatment, ctDNA status, imaging findings, and clinical outcomes to assess potential additional biological or prognostic value |
Up to 5 years
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- 1-10- 72-122-25
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .